Indications and uses
Shortens duration of minor nose bleeds.
DrxNoze Nosebleed Relief
- Manufacturer
- ByzMed, LLC | Oasis Health Products, Inc.
- Effective date
- 2014-01-31
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:05:24
Label at a glance#
ProductDrxNoze Nosebleed Relief
Active ingredientACHILLEA MILLEFOLIUM, MARRUBIUM VULGARE, STACHYS OFFICINALIS, URTICA DIOICA
Label structure9 sections
Dosage and administration
Adults and children 6 years and older: 1. Peel back tab on package to expose swab. 2. Remove swab from package. 3. Blow nose gently to remove excess blood from nasal passage. 4. Apply swab to affected area in nasal passage. 5. Pinch nostril with swab in place (tilt chin slightly downward). 6. Keep swab in place for 1 minute. 7. Remove swab and gently blow out excess blood from nostril. 8. If bleeding persists, twi...
Contacts and useful links#
Websitewww.drxnoze.com
www.DrxNoze.com
www.DrxNoze.comLabel contents#
Full prescribing information#
Active ingredients
Achillea millefolium 1X, Marrubium vulgare 1X, Stachys betonica 1X, Urtica dioica 1X
Purpose
Astringent
Keep Out of Reach of Children
Keep out of the reach of children.
Uses
Shortens duration of minor nose bleeds.
Warnings
For Nasal Passage Use Only. Do not use if you are allergic to any ingredient in this product.
When using this product
- Avoid contact with eyes.
- Do not use for deep or puncture wounds, animal bites, or serious burns.
- In case of accidental contact with eyes, flush with water and immediately seek professional help.
- Keep out of the reach of children.
- Each applicator is designed for one person, single use.
- If pregnant or breastfeeding, ask a health professional before use.
- Consult a physician if bleeding persists for longer than 30 minutes.
- Consult a physician if symptoms persist for more than 7 days or worsen.
- Do not use if seal is broken.
- Children under 6 years of age: consult a physician before use.
- In case of overdose, get medical help or contact a Poison Control Center immediately.
Directions
Adults and children 6 years and older:
1. Peel back tab on package to expose swab.
2. Remove swab from package.
3. Blow nose gently to remove excess blood from nasal passage.
4. Apply swab to affected area in nasal passage.
5. Pinch nostril with swab in place (tilt chin slightly downward).
6. Keep swab in place for 1 minute.
7. Remove swab and gently blow out excess blood from nostril.
8. If bleeding persists, twist swab ½ turn and reinsert for 1-2 minutes or until bleeding stops.
9. Dispose of swab after use.
Inactive Ingredients
aloe vera, citric acid, glycerin, hydroxyethyl-cellulose, polysorbate 20, potassium sorbate, purified water, sodium benzoate, sodium chloride
Other Information
Store at 68-77°F (20-25°C)
Package/Label Principal Display Panel
DRxNOZE® NOSEBLEED RELIEF
Works Fast! Natural Active Ingredients!
- Helps natural blood clotting
- Easy to use, works quickly
- No stinging
- Effective stopping rebleeds
- No strips to clog nostrils
- Pharmacist developed
Contains 5 Nasal Swabs (1 swab per dose)
Homeopathic
Manufactured and distributed for:
ByzMed, LLC
Cottage Grove, WI 53527 USA
Made in the USA
US Patent 8,414,935
Foreign application pending
©2013 Byzmed, LLC
Questions or comments? Call (866-473-1740) or email us at: customerservice@DrxNoze.com.
Visit us at www.DrxNoze.com
These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.
Carton Label – Front
- Carton Label – Back
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 58092-001-01 | 2019-11-27 | C162847 | 48780-1 | 9855e2a2-3e7f-60a7-e053-dbdaa90a05bd | DrxNoze® Nosebleed Relief Drug Facts |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 58092-001-01 | DrxNoze Nosebleed Relief | 1.5 mL in 1 BLISTER PACK | SWAB | 1.5 | 1 | |
| 58092-001-01 | DrxNoze Nosebleed Relief | 5 in 1 CARTON | SWAB | 5 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACHILLEA MILLEFOLIUM | ACTIVE INGREDIENT | 2FXJ6SW4PK | 1 | |
| MARRUBIUM VULGARE | ACTIVE INGREDIENT | 7A72MUN24Z | 1 | |
| STACHYS OFFICINALIS | ACTIVE INGREDIENT | UO9989Y17N | 1 | |
| URTICA DIOICA | ACTIVE INGREDIENT | 710FLW4U46 | 1 | |
| ACHILLEA MILLEFOLIUM | ACTIVE MOIETY | 2FXJ6SW4PK | 1 | |
| MARRUBIUM VULGARE | ACTIVE MOIETY | 7A72MUN24Z | 1 | |
| STACHYS OFFICINALIS | ACTIVE MOIETY | UO9989Y17N | 1 | |
| URTICA DIOICA | ACTIVE MOIETY | 710FLW4U46 | 1 | |
| ALOE VERA LEAF | INACTIVE INGREDIENT | ZY81Z83H0X | 1 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| HYDROXYETHYL CELLULOSE (100 MPA.S AT 2%) | INACTIVE INGREDIENT | R33S7TK2EP | 1 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 1 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 1 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 1 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- DrxNoze Nosebleed Relief
- Achillea Millefolium, Marrubium Vulgare, Stachys Betonica, Urtica Dioica
- ACHILLEA MILLEFOLIUM
- MARRUBIUM VULGARE
- STACHYS OFFICINALIS
- URTICA DIOICA
- ALOE VERA LEAF
- CITRIC ACID MONOHYDRATE
- GLYCERIN
- HYDROXYETHYL CELLULOSE (100 MPA.S AT 2%)
- POLYSORBATE 20
- POTASSIUM SORBATE
- WATER
- SODIUM BENZOATE
- SODIUM CHLORIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 58092-001 | 58092-001-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ACHILLEA MILLEFOLIUM | 2FXJ6SW4PK | ACTIB |
| MARRUBIUM VULGARE | 7A72MUN24Z | ACTIB |
| STACHYS OFFICINALIS | UO9989Y17N | ACTIB |
| URTICA DIOICA | 710FLW4U46 | ACTIB |
| ALOE VERA LEAF | ZY81Z83H0X | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| HYDROXYETHYL CELLULOSE (100 MPA.S AT 2%) | R33S7TK2EP | IACT |
| POLYSORBATE 20 | 7T1F30V5YH | IACT |
| POTASSIUM SORBATE | 1VPU26JZZ4 | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / AURICULAR (OTIC) | 0.04 %w/w | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | CAPSULE / ORAL | 563 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRASYNOVIAL | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION, SOLUTION / INTRAMUSCULAR | 4.8 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRALESIONAL | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION / INTRAVENOUS | 864 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | CONCENTRATE / ORAL | 20 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / RESPIRATORY (INHALATION) | 0.03 %w/v | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SOLUTION / ORAL | 660 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRADERMAL | 7 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYRUP / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INFILTRATION | 3535 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ORAL | 1126 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GEL / TOPICAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / TOPICAL | 0.2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SOLUTION / OPHTHALMIC | 0.9 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY / NASAL | 30 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAMUSCULAR | 0.05 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | SPRAY, METERED / NASAL | 40 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM, EXTENDED RELEASE / TRANSDERMAL | 1.38 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR | 45 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SHAMPOO / TOPICAL | 150 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / EPIDURAL | 0.02 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SUSPENSION / ORAL | 840 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBMUCOSAL | 16 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EFFERVESCENT / ORAL | 460 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | TABLET, DELAYED RELEASE / ORAL | 0.34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / IONTOPHORESIS | 0.6 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LOTION / TOPICAL | 0.3 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / PERIDURAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / AURICULAR (OTIC) | 18 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | PASTE / ORAL | 28 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / TOPICAL | 0.86 %w/v | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | LOTION / TOPICAL | 2000 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRALESIONAL | 0.9 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAOCULAR | 1 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a47683ea-aa14-433c-bb8f-3aa808595645 | a47683ea-aa14-433c-bb8f-3aa808595645 | 2014-01-31 | Warnings | a47683ea-aa14-433c-bb8f-3aa808595645 a47683ea-aa14-433c-bb8f-3aa808595645 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.